Pharmaceutical services and inpatient drug costs in bone marrow transplantation

Abstract

A survey of U.S. bone marrow transplantation (BMT) programs was conducted to determine the role of pharmaceutical services in those programs and the pharmacy department resources allocated to support them. Surveys were sent to 92 U.S. BMT programs to solicit the following information: characteristics of the institution and the BMT program, extent of pharmacist involvement in the BMT program, and pharmacy resource allocation to the program. Fifty-five responses were received (60% response rate). BMT pharmacists were employed by 53 of these institutions (a total of 66 pharmacists). BMT pharmacists at 49 of the 53 institutions (92%) received their salary from the department of pharmacy. Common BMT pharmacist responsibilities included managing adverse effects (100% of respondents), adjusting medication doses (96%), providing drug information (94%), participating in BMT team rounds (87%), maintaining medication profiles (85%), and developing medication protocols (81%). Inpatient BMT-related drug costs (reported by 37 respondents) averaged 12% of the pharmacy's annual inpatient drug budget. One or more pharmacists were members of the BMT team at 46 of 53 institutions. BMT-related drug costs accounted for 12% of the total inpatient drug budget at the 37 institutions reporting cost data.